Comparative Pharmacology
Head-to-head clinical analysis: DIVALPROEX SODIUM versus TEGRETOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIVALPROEX SODIUM versus TEGRETOL.
DIVALPROEX SODIUM vs TEGRETOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases brain concentrations of gamma-aminobutyric acid (GABA), blocks voltage-gated sodium channels, and modulates T-type calcium channels.
Voltage-gated sodium channel blocker; stabilizes neuronal membranes and inhibits repetitive firing. Also inhibits glutamate release and enhances GABA activity.
10-15 mg/kg/day orally in divided doses; increase by 5-10 mg/kg/week; maximum 60 mg/kg/day. Extended-release: 25 mg/kg/day orally; increase by 15 mg/kg/day at weekly intervals; maximum 60 mg/kg/day.
Initial: 200 mg orally twice daily; increase by 200 mg/day at weekly intervals. Maintenance: 800-1200 mg/day in 2-4 divided doses. Maximum dose: 1600 mg/day. Extended-release: 200-400 mg twice daily.
None Documented
None Documented
9-16 hours (terminal); shorter in children (6-9 hours) and longer in hepatic disease or elderly; clinical context: twice-daily dosing provides stable trough concentrations.
Single dose: 25–65 hours (mean ~35 h); chronic therapy: 12–17 hours due to autoinduction; clinical context: requires 3–4 weeks to reach steady-state after dose adjustment.
Renal: <3% unchanged; primarily hepatic metabolism (glucuronidation, beta-oxidation, cytochrome P450), metabolites eliminated renally; fecal: negligible.
Primarily hepatic metabolism; ~72% excreted in urine (as metabolites, <2% unchanged), ~28% excreted in feces via bile.
Category D/X
Category C
Anticonvulsant
Anticonvulsant